Read the latest updates about BioMarin and learn more about our science, our people and the communities we support.
February 5, 2025
January 13, 2025
January 6, 2025
November 16, 2024
November 6, 2024
As the newly appointed co-chairs of our Black Employee Resource Group (BERG), Ashley R. Holland and Will Thompson are focused on driving conversations and action around health equity and aiding in the retention and advancement of Black employees. Ashley and Will shared what they are excited about this year, including during Black History Month, as they step into their new roles.
Ribonucleic acid (RNA) is a molecule that transfers genetic information from DNA, with different types of RNA playing critical roles in how genes are expressed via the production of proteins. Evidence suggests that RNA-targeted medicines have the potential to address specific changes in a gene or regulate protein production, particularly in genetic conditions characterized by limited production of key proteins. Our scientists are working to understand how leveraging RNA-targeted therapies may provide new ways to target the root causes of certain genetic conditions, including through strategic research collaborations with CAMP4 Therapeutics and MiNA Therapeutics.
As we wrap up this year and look ahead to 2025, we are more driven than ever to deliver on our purpose: to be the biotech leader that translates the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The BioMarin 8 – our core Operating Principles – provide the framework for how we work together every day to fulfill that purpose. Thank you to all our employees for your hard work and dedication throughout 2024 – we look forward to what we will accomplish together in the new year.
We’re looking forward to the #TruePKU meeting next year, which will be the first opportunity for U.S. regulators to hear directly from the #PKU community in a public forum in more than a decade. We’re proud to support the National PKU Alliance's efforts to integrate the perspectives of people living with PKU into the process of developing new therapeutic options and are grateful that the #FDA has made this opportunity possible by granting this EL-PFDD.